Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus
Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus
复制标题
DOI：
10.1186/1743-7075-7-83
复制
发表时间：
2010-11-12
影响因子：
4.5
通讯作者：
Togane, Michiko
中科院分区：
文献类型：
--
作者：
Ito, Hiroyuki;Ishida, Hidenori;Togane, Michiko
背景资料：目的：探讨二甲双胍对非肥胖2型糖尿病患者血糖控制的长期效果。方法：对213例二甲双胍治疗1年以上的2型糖尿病患者进行回顾性研究。对临床参数进行了为期3年的调查。结果：HbA 1c水平较基线时明显降低，其中肥胖组105例，体重指数≥ 25 kg/m2;非肥胖组108例，体重指数<25 kg/m2。非肥胖组和肥胖组的HbA 1c病程相似，而非肥胖组控制血糖所需的二甲双胍剂量显著低于肥胖组。非肥胖组和肥胖组的HbA 1c在12个月时分别降低1.2%和1.1%，在24个月时分别降低0.9%和0.9%，在36个月时分别降低0.8%和1.0%。BMI在观察期间没有变化。两组中大约有一半的患者在开始二甲双胍治疗后不需要额外的降糖药物或减少其他治疗。结论：本研究证实了二甲双胍对非肥胖（BMI < 25 kg/m2）糖尿病患者的长期有益作用。即使在本研究的观察期后，该效应似乎仍得以维持，因为二甲双胍在非肥胖组中仅限于相对较低的剂量，并且观察到的血糖控制随时间的恶化可能会通过增加二甲双胍的剂量而减弱。
Background: We aimed to investigate the long-term effect of metformin on the blood glucose control in non-obese patients with type 2 diabetes mellitus.Methods: A retrospective study was performed in 213 patients with type 2 diabetes mellitus under the administration of metformin for more than one year. The clinical parameters were investigated for 3 years. The obese and non-obese individuals were defined as a body mass index (BMI) of 25 kg/m(2) or over (n = 105) and a BMI of less than 25 kg/m(2) (n = 108), respectively.Results: HbA1c levels were significantly decreased compared with those at the baseline time. The course of HbA1c was similar between the non-obese and the obese groups, while the dose of metformin required to control blood glucose was significantly lower in the non-obese group than in the obese group. The reductions in HbA1c were 1.2% and 1.1% at 12 months, 0.9% and 0.9% at 24 months, and 0.8% and 1.0% at 36 months in the non-obese and obese groups, respectively. BMI did not change during the observation periods. Approximately half of all patients required no additional antidiabetic agents or a reduction in other treatments after the initiation of metformin in either of the two groups.Conclusions: The present study demonstrated the long-term beneficial effect of metformin in non-obese (BMI < 25 kg/m(2)) diabetic patients. This effect appears to be maintained even after the observation period of this study, because metformin was limited to a relatively low dose in the non-obese group and the observed worsening in glycemic control over time can probably be attenuated by increasing the dose of metformin.